Scale -

  • PAT is 671 Rs Cr; Annual Growth is 15 %
  • Revenue is 7345 Rs Cr; Continuous Growth over 3 years
  • Ebitda is 1173 Rs Cr; Continuous Growth over 3 years

Profitability -

  • PBDIT Margin is 15.96 %; Continuous Growth over 3 years; in Bottom Quartile
  • PAT Margin is 9.13 %; in Bottom Quartile
  • Quarterly Ebitda Margin is 15 %; in Bottom Quartile
  • Quarterly Profit margin is 8 %; in Bottom Quartile

Return -

  • Asset Turnover is 89 %; Continuous Decline over 3 years
  • ROCE is 13.84 %; in Bottom Quartile

Efficiency -

  • Operating cash flow is 783 Rs Cr; Annual Growth is 790 %
  • Inventory Turnover Ratio is 3.06; 5 Year CAGR is 41 %; in Bottom Quartile
  • Quick Ratio is 0.79; in Bottom Quartile

Solvancy -

  • Contingent Liabilities is 352 Rs Cr; Annual Growth is 86 %; Continuous Growth over 3 years
  • Debt/Equity is 0.24; Continuous Growth over 3 years
  • Total Debt is 1361 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 21 %

Quality -

  • Operating cashflow/ebitda is 67 %; Annual Growth is 697 %
  • Operating cashflow/PAT is 117 %; Annual Growth is 671 %
  • Exceptional Items/PBT is -10 %; Annual Decline is -630 %; in Bottom Quartile
  • Current Tax/PAT is 19 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is -4 %; in Bottom Quartile
  • Other Expenses/Total Expenses is 37 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector
Major Subsidiaries/Associates
Key Clients

Products

Products
Product details

Operations

Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Alembic Pharma Gets USFDA Nod for Cancer Drug
Read More
  • Past/current
Alembic Pharmaceuticals secures USFDA approval for Venetoclax tablets
Read More
  • Past/current
Alembic Pharma Gets USFDA Final Approval for Generic Valganciclovir Oral Solution
Read More
  • Past/current